W. Mcguire, Steroid Hormone Receptors in Breast Cancer Treatment Strategy, Recent Prog Horm Res, vol.36, pp.135-156, 1980.
DOI : 10.1016/B978-0-12-571136-4.50010-3

C. Osborne, Mechanisms for tamoxifen resistance in breast cancer: Possible role of tamoxifen metabolism, The Journal of Steroid Biochemistry and Molecular Biology, vol.47, issue.1-6, pp.83-89, 1993.
DOI : 10.1016/0960-0760(93)90060-A

B. Katzenellenbogen, M. Montano, K. Ekena, M. Herman, and E. Mcinerney, Antiestrogens: Mechanisms of action and resistance in breast cancer, Breast Cancer Research and Treatment, vol.55, issue.Suppl2, pp.23-38, 1997.
DOI : 10.1023/A:1005835428423

S. Ali and R. Coombes, ENDOCRINE-RESPONSIVE BREAST CANCER AND STRATEGIES FOR COMBATING RESISTANCE, Nature Reviews Cancer, vol.104, issue.2, pp.101-112, 2002.
DOI : 10.1126/science.277.5331.1508

J. Macgregor and V. Jordan, Basic guide to the mechanisms of antiestrogen action, Pharmacol Rev, vol.50, pp.151-196, 1998.

H. Crewe, S. Ellis, M. Lennard, and G. Tucker, Variable contribution of cytochromes p450 2d6, 2c9 and 3a4 to the 4-hydroxylation of tamoxifen by human liver microsomes, Biochemical Pharmacology, vol.53, issue.2, pp.171-178, 1997.
DOI : 10.1016/S0006-2952(96)00650-8

H. Crewe, L. Notley, R. Wunsch, M. Lennard, and E. Gillam, Metabolism of Tamoxifen by Recombinant Human Cytochrome P450 Enzymes: Formation of the 4-Hydroxy, 4'-Hydroxy and N-Desmethyl Metabolites and Isomerization of trans-4-Hydroxytamoxifen, Drug Metabolism and Disposition, vol.30, issue.8, pp.869-874, 2002.
DOI : 10.1124/dmd.30.8.869

V. Wiebe, C. Osborne, W. Mcguire, and M. Degregorio, Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors., Journal of Clinical Oncology, vol.10, issue.6, pp.990-994, 1992.
DOI : 10.1200/JCO.1992.10.6.990

C. Osborne, Tamoxifen in the treatment of breast cancer, N Engl J Med, vol.339, pp.1609-1618, 1998.

F. Zhang, P. Fan, X. Liu, L. Shen, R. Van-breeman et al., -quinone, Chemical Research in Toxicology, vol.13, issue.1, pp.53-62, 2000.
DOI : 10.1021/tx990145n

URL : https://hal.archives-ouvertes.fr/hal-01258459

P. Fan and J. Bolton, Bioactivation of tamoxifen to metabolite E quinone methide: reaction with glutathione and DNA, Drug Metab Dispos, vol.29, pp.891-896, 2001.

S. Dehal and D. Kupfer, Evidence that the catechol 3,4-dihydroxyta- moxifen is a proximate intermediate to the reactive species binding covalently to proteins, Cancer Res, vol.56, pp.1283-1290, 1996.

I. White, Tamoxifen: Is it Safe? Comparison of Activation and Detoxication Mechanisms in Rodents and in Humans, Current Drug Metabolism, vol.4, issue.3, pp.223-239, 2003.
DOI : 10.2174/1389200033489451

K. Ramakrishna, P. Fan, C. Boyer, D. Dalvie, and J. Bolton, Oxo Substituents Markedly Alter the Phase II Metabolism of ??-Hydroxybutenylbenzenes:?? Models Probing the Bioactivation Mechanisms of Tamoxifen, Chemical Research in Toxicology, vol.10, issue.8, pp.887-894, 1997.
DOI : 10.1021/tx970060r

G. Chen, S. Yin, S. Maiti, and X. Shao, 4-Hydroxytamoxifen sulfation metabolism, Journal of Biochemical and Molecular Toxicology, vol.10, issue.6, pp.279-285, 2002.
DOI : 10.1002/jbt.10048

P. Allen and J. Kolesar, NAD(P)H: quinone oxidoreductase enhances proliferation inhibition by 4-hydroxytamoxifen, Anticancer Res, vol.22, pp.1475-1480, 2002.

J. Williams and D. Phillips, Mammary expression of xenobiotic metabolizing enzymes and their potential role in breast cancer, Cancer Res, vol.60, pp.4667-4677, 2000.

C. Osborne, V. Wiebe, W. Mcguire, D. Ciocca, and M. Degregorio, Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients., Journal of Clinical Oncology, vol.10, issue.2, pp.304-310, 1992.
DOI : 10.1200/JCO.1992.10.2.304

B. Brockdorff, J. Skouv, B. Reiter, and A. Lykkesfeldt, Increased expression of cytochrome p450 1A1 and 1B1 genes in anti-estrogen-resistant human breast cancer cell lines, International Journal of Cancer, vol.30, issue.6, pp.902-906, 2000.
DOI : 10.1002/1097-0215(20001215)88:6<902::AID-IJC10>3.0.CO;2-C

P. Fritz, T. Murdter, M. Eichelbaum, I. Siegle, M. Weissert et al., Microsomal Epoxide Hydrolase Expression as a Predictor of Tamoxifen Response in Primary Breast Cancer: A Retrospective Exploratory Study With Long-Term Follow-Up, Journal of Clinical Oncology, vol.19, issue.1, pp.3-9, 2001.
DOI : 10.1200/JCO.2001.19.1.3

I. Bieche, B. Parfait, I. Laurendeau, I. Girault, M. Vidaud et al., Quantification of estrogen receptor ?? and ?? expression in sporadic breast cancer, Oncogene, vol.20, issue.56, pp.8109-8115, 2001.
DOI : 10.1038/sj.onc.1204917

J. Hanley and B. Mcneil, The meaning and use of the area under a receiver operating characteristic (ROC) curve., Radiology, vol.143, issue.1, pp.29-36, 1982.
DOI : 10.1148/radiology.143.1.7063747

E. Kaplan and P. Meier, Nonparametric Estimation from Incomplete Observations, Journal of the American Statistical Association, vol.37, issue.282, pp.457-481, 1958.
DOI : 10.1214/aoms/1177731566

D. Cox, Regression Models and Life-Tables, J R Stat Soc (B), vol.34, pp.187-220, 1972.
DOI : 10.1007/978-1-4612-4380-9_37

M. Larsen, W. Angus, P. Brake, S. Eltom, K. Sukow et al., Characterization of CYP1B1 and CYP1A1 expression in human mammary epithelial cells: role of the aryl hydrocarbon receptor in polycyclic aromatic hydrocarbon metabolism, Cancer Res, vol.58, pp.2366-2374, 1998.

R. Goth-goldstein, M. Stampfer, C. Erdmann, and M. Russell, Interindividual variation in CYP1A1 expression in breast tissue and the role of genetic polymorphism, Carcinogenesis, vol.21, issue.11, pp.2119-2122, 2000.
DOI : 10.1093/carcin/21.11.2119

Z. Huang, M. Fasco, H. Figge, K. Keyomarsi, and L. Kaminsky, Expression of cytochromes P450 in human breast tissue and tumors, Drug Metab Dispos, vol.24, pp.899-905, 1996.

M. Iscan, T. Klaavuniemi, T. Coban, N. Kapucuoglu, O. Pelkonen et al., The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue, Breast Cancer Research and Treatment, vol.169, issue.1, pp.47-54, 2001.
DOI : 10.1023/A:1012526406741

C. Ambrosone, C. Sweeney, B. Coles, P. Thompson, G. Mcclure et al., Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer, Cancer Res, vol.61, pp.7130-7135, 2001.

C. Sweeney, G. Mcclure, M. Fares, A. Stone, B. Coles et al., Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism, Cancer Res, vol.60, pp.5621-5624, 2000.

C. Maugard, J. Charrier, A. Pitard, L. Campion, O. Akande et al., Genetic polymorphism at the glutathione S-transferase (GST) P1 locus is a breast cancer risk modifier

W. Zheng, A. Deitz, D. Campbell, W. Wen, J. Cerhan et al., N-acetyltransferase 1 genetic polymorphism , cigarette smoking, well-done meat intake, and breast cancer risk, Cancer Epidemiol Biomarkers Prev, vol.8, pp.233-239, 1999.

F. Pompeo, E. Brooke, A. Kawamura, A. Mushtaq, and E. Sim, The pharmacogenetics of NAT: structural aspects, Pharmacogenomics, vol.3, issue.1, pp.19-30, 2002.
DOI : 10.1517/14622416.3.1.19

E. Sim, M. Payton, M. Noble, and R. Minchin, An update on genetic, structural and functional studies of arylamine N-acetyltransferases in eucaryotes and procaryotes, Human Molecular Genetics, vol.9, issue.16, pp.2435-2441, 2000.
DOI : 10.1093/hmg/9.16.2435

J. Williams, E. Stone, G. Fakis, N. Johnson, J. Cordell et al., N-Acetyltransferases, sulfotransferases and heterocyclic amine activation in the breast, Pharmacogenetics, vol.11, issue.5, pp.373-388, 2001.
DOI : 10.1097/00008571-200107000-00002

Y. Geylan, S. Dizbay, and T. Guray, Arylamine N-acetyltransferase activities in human breast cancer tissues, Neoplasma, vol.48, pp.108-111, 2001.